Congress Symposia

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

Overview

Speakers:
Laurie Ann Holmes
Giselle Wilson
Cheryl Page
Rachel Nielsen
20.10.2023
Duration: 25 mins 19 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 2

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 2

Overview

Speakers:
Laurie Ann Holmes
Giselle Wilson
Cheryl Page
Rachel Nielsen
20.10.2023
Duration: 19 mins 47 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 3

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 3

Overview

Speakers:
Laurie Ann Holmes
Giselle Wilson
Cheryl Page
Rachel Nielsen
20.10.2023
Duration: 18 mins 4 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

Evolving Survival Outcomes with CAR T in 2L DLBCL

Evolving Survival Outcomes with CAR T in 2L DLBCL

Overview

Speakers:
Dr. Jason Westin
13.06.2023
Duration: 10 mins 27 secs

As part of Kite’s symposia at ICML 2023 entitled “CAR T in 2L DLBCL: A case study”, Dr. Westin presents three of his patients with DLBCL who require treatment in the 2L setting, and reviews clinical evidence to guide potential treatment options.

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Overview

Speakers:
Dr. Bijal Shah
Dr. Florence Rabian
08.06.2023
Duration: 27 mins 21 secs

As part of Kite’s symposia at EHA 2023 entitled “Managing R/R Adult ALL in the CAR T Era”, Dr. Shah and Dr. Rabian discuss CAR T treatment approaches in R/R adult ALL, including clinical trial and real-world data updates, as well as present real patient cases.

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

Overview

Speakers:
Dr. Sita Bhella
Dr. Caron Jacobson
02.06.2023
Duration: 22 mins 33 secs

These are recordings of Kite’s symposia at CTTC 2023 entitled “CAR T Cell Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients”. In Part 1, Dr. Sita Bhella discusses the Canadian experience with CAR T cell therapy for R/R LBCL from referral to follow up, including best practices on integrating CAR T therapy into clinical practice. In Part 2, Dr. Caron Jacobson shares key learnings from the US experience incorporating CAR T therapy as second-line treatment. 

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 2

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 2

Overview

Speakers:
Dr. Sita Bhella
Dr. Caron Jacobson
02.06.2023
Duration: 20 mins 34 secs

These are recordings of Kite’s symposia at CTTC 2023 entitled “CAR T Cell Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients”. In Part 1, Dr. Sita Bhella discusses the Canadian experience with CAR T cell therapy for R/R LBCL from referral to follow up, including best practices on integrating CAR T therapy into clinical practice. In Part 2, Dr. Caron Jacobson shares key learnings from the US experience incorporating CAR T therapy as second-line treatment. 

Survival in R/R DLBCL with CAR T: How long can we go?

Survival in R/R DLBCL with CAR T: How long can we go?

Overview

Speakers:
Dr. Jason Westin
19.03.2022
Duration: 16 mins 9 secs

As part of Kite’s symposia at EBMT 2022 entitled “5 years and counting: Building survival in lymphoma with CAR T”, Dr. Westin provides clinical trial and real-world data updates on CAR T therapy for relapsed or refractory large B-cell lymphoma.

Navigating the New Paths to Redefine Survival in MCL Treatment

Navigating the New Paths to Redefine Survival in MCL Treatment

Overview

Speakers:
Profs. Andy Davies and Georg Hess
09.06.2021
Duration: 25 mins 16 secs

As part of Kite’s symposia at EHA 2021 entitled “Redefining survival in adult hematological malignancies: The role of CAR T”, Profs. Davies and Hess highlight unmet needs in R/R MCL, discuss emerging therapies including CAR T, and provide clinical guidance in navigating the patient journey.